Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.
Ethical Issues in Clinical Research. Getting an IRB approval and role of NHRC
Dr Namita Ghimire - Nepal Health Research Council (NHRC), Kathmandu, Nepal
Ethical Issues in Clinical Research. Getting an IRB approval and role of NHRC ( Dr Namita Ghimire - Nepal Health Research Council (NHRC), Kathmandu, Nepal )
25 Sep 2022
ESMO 2022: Highlights, commentary and analysis
Dr Bishal Gyawali - Queen's University, Kingston, Canada
ESMO 2022: Highlights, commentary and analysis ( Dr Bishal Gyawali - Queen's University, Kingston, Canada )
12 Sep 2022
ESMO 2022: Latest in PARP inhibitors for metastatic prostate cancer
Dr Neal Shore, Dr Pasquale Rescigno, Prof Noel Clarke and Dr Friederike Schlürma...
ESMO 2022: Latest in PARP inhibitors for metastatic prostate cancer ( Dr Neal Shore, Dr Pasquale Rescigno, Prof Noel Clarke and Dr Friederike Schlürmann )
11 Sep 2022
Low-dose nivolumab leads to improved overall survival for head and neck cancer p...
Dr Bishal Gyawali - Queen's University, Kingston, Canada
Low-dose nivolumab leads to improved overall survival for head and neck cancer patients ( Dr Bishal Gyawali - Queen's University, Kingston, Canada )
19 Jul 2022
ASCO 2022: Highlights and analysis
Dr Bishal Gyawali - Queen's University, Kingston, Canada
ASCO 2022: Highlights and analysis ( Dr Bishal Gyawali - Queen's University, Kingston, Canada )
6 Jun 2022
ASCO 2022: Latest in prostate cancer, including PARP inhibitors
Dr Neal Shore, Prof Cora Sternberg, Prof Eleni Efstathiou and Prof Phil Cornford
ASCO 2022: Latest in prostate cancer, including PARP inhibitors ( Dr Neal Shore, Prof Cora Sternberg, Prof Eleni Efstathiou and Prof Phil Cornford )
6 Jun 2022
ASCO 2022: Latest in EGFR positive NSCLC
Prof Benjamin Besse, Dr Anna Minchom, Dr Antonio Passaro and Dr Enriqueta Felip
ASCO 2022: Latest in EGFR positive NSCLC ( Prof Benjamin Besse, Dr Anna Minchom, Dr Antonio Passaro and Dr Enriqueta Felip )
5 Jun 2022
Single-agent PD-1 blockade as curative-intent treatment in mismatch repair-defic...
Dr Andrea Cercek - Memorial Sloan Kettering Cancer Centre, Manhattan, New York
Single-agent PD-1 blockade as curative-intent treatment in mismatch repair-deficient locally advanced rectal cancer ( Dr Andrea Cercek - Memorial Sloan Kettering Cancer Centre, Manhattan, New York )
5 Jun 2022
N-803-BCG combination shows promising results in BCG-unresponsive NMIBC
Dr Karim Chamie - UCLA School of Medicine, Los Angeles, USA
N-803-BCG combination shows promising results in BCG-unresponsive NMIBC ( Dr Karim Chamie - UCLA School of Medicine, Los Angeles, USA )
4 Jun 2022
Recent advances in the treatment of patients with exon 20 insertion-positive NSC...
Dr Alfredo Addeo, Prof Nicolas Girard and Prof Natasha Leighl
Recent advances in the treatment of patients with exon 20 insertion-positive NSCLC ( Dr Alfredo Addeo, Prof Nicolas Girard and Prof Natasha Leighl )
21 Apr 2022
PETRA: Next generation PARP1-selective inhibitor AZD5305 in patients with BRCA1/...
Dr Timothy Yap - MD Anderson Cancer Center, Houston, USA
PETRA: Next generation PARP1-selective inhibitor AZD5305 in patients with BRCA1/2, PALB2 or RAD51C/D mutations ( Dr Timothy Yap - MD Anderson Cancer Center, Houston, USA )
13 Apr 2022
EGFR testing: Best practice for NSCLC patients with exon 20 insertions
Dr Antonio Passaro, Dr Umberto Malapelle and Dr Joshua Sabari
EGFR testing: Best practice for NSCLC patients with exon 20 insertions ( Dr Antonio Passaro, Dr Umberto Malapelle and Dr Joshua Sabari )
30 Mar 2022